Geron (GERN) Stock

2023 Update

About Geron

Geron Corporation is a late-stage clinical biopharmaceutical company that focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. Founded in 1990, the company is headquartered in Foster City, California with over 107 full-time employees and an address of 919 East Hillsdale Boulevard, Suite 250 in zip code 94404.

Geron Corporation has made great strides in the research and development of imetelstat, a telomerase inhibitor that inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. In order to promote the successful development and commercialization of this product, Geron Corporation has strategically partnered with a number of both domestic and international organizations.

Geron Corporation maintains a strong commitment to all stakeholders, including their investors, clients, medical professionals, and communities. With a website available to provide the latest news and updates, Geron Corporation continues to be a leader and thought-leader in the biotechnology industry.

In order to contact the company, please call them at 650 473 7700 or visit their website at

Geron's Performance

Geron Corporation has been performing relatively poorly in terms of its financials. Its total cash per share is reported as $0.75, its revenue per share is reported as $0.001, and its operating cashflow is reported as -$139.77 million. Its free cashflow is reported as -$87.06 million, and its operating margins are reported as -30,357.69%. The company’s total debt is reported as $55.84 million, and its gross profits are reported as -$93.67 million.

The company’s revenue growth is reported as -82.90%, and its current ratio is reported as 8.81. Its EBITDA is reported as -$149.64 million, and its return on equity is reported as -70.80%. Its target median price is reported as $5.00, and its recommendation mean as 1.70. Its total revenue is reported as $494k, and its gross margins as 0.00%.

Geron Corporation has a target high price of $6.00, a target low price of $4.00, and a target median price of $4.83. Its profit margins are reported as 0.00%, its earnings growth is not currently reported, and its current price is reported as $3.07. Its EBITDA margins are reported as 0.00%, its debt to equity is reported as 17.13, and its return on assets is reported as -30.08%. Finally, its quick ratio is reported as 8.71, and it has a total of 6 analyst opinions.

How does Geron Perform During a Recession?

No business is immune to the economic challenges posed by a recession, and Geron Corporation is no different. Since its founding, the company has had to find ways to remain competitive and navigate through financial downturns. With a commitment to innovation and customer focus, Geron Corporation has maintained a strong financial performance even during a recession.

To maintain financial stability during recessionary periods, Geron Corporation leverages a number of strategies, including streamlining their research and development effort to focus on their most promising projects, reducing operational and administrative expenses, and entering into strategic partnerships. In addition, the company also takes measures to ensure that their products continue to remain competitive during a recession. This includes offering attractive pricing and engaging in aggressive marketing efforts to maintain a presence in the marketplace.

Furthermore, the company’s commitment to financial responsibility also extends to their investors. Geron Corporation works to ensure that investors are kept informed of the company’s progress in an effort to maintain their trust and confidence. Through regular financial disclosures and newsletters, the company ensures that investors have the information they need to make informed decisions.

Geron Corporation is able to succeed during a recession through its commitment to research and development, its focus on financial responsibility, and its aggressive marketing approach. By leveraging these strategies, the company is able to remain profitable and maintain a strong presence in the biotechnology industry, even during tough economic times.

How does Geron Perform During High Inflation Economy?

When facing high inflation, Geron Corporation must adjust its long-term strategies in order to remain successful and competitive. High inflation can have a significant impact on the company’s profitability, due to rising prices on necessary materials, leading to a decrease in its operating margins. This could lead to decreased spending on research and development, which could negatively affect Geron Corporation’s ability to compete with its peers in the biotechnology industry.

In order to counter these challenges, Geron Corporation has implemented several measures. These include utilizing hedging strategies to protect their cash flows, increasing investments in research and development, and pursuing new partnerships with companies in both domestic and international markets.

Geron Corporation has also made efforts to ensure that their pricing is competitive with other companies in the same field, while also adhering to the regulations and guidelines set by different governments. This helps the company maintain a positive reputation while still remaining cost-effective.

Ultimately, Geron Corporation’s response to high inflation requires careful planning and execution. With strategic investments in both research and development and partnerships with other organizations, the company has been able to remain successful and competitive even in difficult economic times.

What Are the Risks Associated to Geron (GERN)?

Given the company’s weak financial performance and outlook, it is important for investors to consider the risks associated with investing in Geron Corporation. These risks include: (1) the loss of investments due to the company’s poor financial performance, (2) potential failure of imetelstat to reach regulatory approval, (3) delays in imetelstat’s commercial launch, (4) increased competition from established and new drug developers, (5) the failure to secure new collaborative partnerships and strategic alliances, (6) economic uncertainties, (7) potential changes in healthcare regulations, (8) exposure to legal risks, and (9) exposure to any future legal proceedings or litigation.